Efficacy And Safety Of Exenatide Versus Saxagliptin Combined With Metformin In Patients With Type2Diabetes Mellitus

Objective: To compare the efficacy and safety between Exenatide andSaxagliptin combined with metformin in type2diabetes mellitus(T2DM).Methods: After6weeks introduction treatment stage with metformin,patients with T2DM were randomly divided into two groups: the Exenatidegroup (5ug, bid, n=34)and the Saxagliptin group (5mg, qd, n=37), bothwere in combination of metformin for16weeks. The main index of theeffect was the change of Glycosylated hemoglobin (HbA1c), the secondaryindex of the effect were the percentage of HbA1c7.0%and the declineof Fasting plasma glucose (FPG).Results: Both Exenatide and Saxagliptin could effectively control theblood glucose levels (P <0.01). The effect of Exenatide on HbA1c and FPGwas more significant than that of Saxagliptin did (P <0.05), however, therewas no significant difference between the two groups on the control rates ofHbA1c (P>0.05). Furthermore, the effect of Exenatide on body weight andSBP was more significant than Saxagliptin did (P <0.05). The adverse events of the two groups were slight, and there was no hypoglycemia in twogroups, all of the patients could complete this clinical trials.Conclusion: Both Exenatide and Saxagliptin could effectively controlthe blood glucose levels in Type2diabetes mellitus. Exenatide may be moreconducive to patients accompanied with obesity and high blood pressure.